#ЕУзаТебе
Moonstone Monitoring System: Precise Control in the Pharmaceutical Industry
In the pharmaceutical industry, product quality and safety directly depend on strict compliance with prescribed storage and production conditions. Even the smallest deviation can lead to serious consequences, which is why precise and reliable condition control represents one of the key requirements in this sector, from both regulatory and operational perspectives.
In response to the high standards of the pharmaceutical industry, the team at Laboratorija developed the Moonstone Monitoring System, a technological solution designed for continuous monitoring and management of critical parameters throughout the production and storage of sensitive pharmaceutical products. The system enables real-time measurement of temperature and other relevant conditions, delivering a level of precision and reliability required for handling sensitive pharmaceutical products, exceeding the capabilities of standard sensor-based solutions.
Support from the Innovation Fund and the European Union played a significant role in the development of this innovative solution, enabling faster development, testing, and technological advancement of the system. In addition, collaboration with the Faculty of Pharmacy provided a strong scientific foundation for the project, as well as continuous validation of the solution under conditions closely resembling real pharmaceutical working environments.
The Moonstone Monitoring System was designed not only as a data-recording tool but also as a solution for the timely identification of potential risks. This approach enables pharmaceutical companies to achieve higher operational safety, reduce losses, and plan processes more reliably. Thanks to advanced analytical capabilities, users can respond proactively and prevent situations that could compromise the quality, stability, and safety of sensitive products.
“One of our priorities during development was gaining a deeper understanding of users’ everyday needs,” emphasizes Aleksandar Panovski from Laboratorija. “Our goal was to create a system that combines high technical reliability with ease of use in real working environments, without placing additional burdens on users.”
After establishing a stable and precise core system, the team continued with further enhancements. In the next development phase, elements of machine learning and artificial intelligence were integrated to enable the prediction of potential disruptions in storage and production processes. This transition shifts the system from a reactive to a preventive approach, reducing risks before actual problems occur.
Further system development is focused on practical application and gradual implementation in production environments. User feedback remains an important component of the final optimization process, with the aim of adapting the solution to different operational scenarios in pharmaceutical practice prior to wider commercial deployment.
The Moonstone Monitoring System represents a combination of expertise, technological innovation, and institutional support, offering clear applicability and significant potential for use in the pharmaceutical industry, both in domestic and international markets, where reliability and risk prevention play a decisive role.
Direct Grant - Increased innovation capacity and growth of SMEs is signed between the Innovation Fund and Ministry of Finance - the Department for Contracting and Financing of EU Funded Programs (CFCU) provides funds for the continuation of Mini Grants Program, Matching Grants Program and Collaborative Grant Scheme Program. The total budget of the Direct Grant Agreement is EUR 26 million, of which EUR 16 million is from the European Union Pre-Accession Assistance for 2019 (IPA 2019) and EUR 10 million is from the budget of the Republic of Serbia, under the Ministry of Science, Technological Development and Innovation. The amount allocated for financing approved projects under the Mini Grants Program, Matching Grants Program and Collaborative Grant Scheme Program financed under this Direct Grant Agreement is EUR 20.6 million. More about the project can be found on https://www.inovacionifond.rs/en/